Glypican-3-specific modified aptamer and use thereof
AssigneeAptamer Sciences Inc.
InventorsJo Woon Yi Lee, Youndong Kim, Da Som Lee, Jeong Kyun Lee, Daekyun Lee, So Ryong Lim
Life of this patent
Estimating the term…
Abstract
Provided are a glypican-3 (GPC3)-specific modified aptamer, and prevention or treatment of hepatoma using the same. The glypican-3-specific modified aptamer of the present invention specifically binds to glypican-3 to be internalized into hepatoma cells, and exhibits anticancer activity through an anticancer agent bound to the aptamer, and therefore, has a selective anticancer effect only for GPC3-expressing hepatoma cells without affecting normal hepatocytes.
Claims11
A modified aptamer comprising a nucleic acid aptamer specifically binding to glypican-3 (GPC3) and an anticancer agent, wherein the nucleic acid aptamer consists of any one selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 11 and SEQ ID NO:
- 13 to SEQ ID NO:
- 25.
A nucleic acid aptamer specifically binding to glypican-3, the nucleic acid aptamer consisting of any one nucleotide sequence selected from the group consisting of SEQ ID NO:
- 6 to SEQ ID NO:
- 11 and SEQ ID NO:
- 13 to SEQ ID NO:
- 25.
Dependencies are inferred from the claim text.